JPI 289

Drug Profile

JPI 289

Alternative Names: JI-6289; JPI-289

Latest Information Update: 07 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Anti-ischaemics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Stroke in South Korea (IV) (NCT03062397)
  • 26 Nov 2013 Phase-I clinical trials in Stroke (in volunteers) in South Korea (IV)
  • 19 Nov 2013 JPI 289 is available for licensing as of 19 Nov 2013. https://www.jeilpharm.co.kr/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top